| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T637 |
0-428 |
Sentence |
denotes |
Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5 |
| T638 |
429-726 |
Sentence |
denotes |
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14 |
| T639 |
727-912 |
Sentence |
denotes |
Secondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020 |
